Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and
rationally designed drug screens
Liu L, Strange A, Lee S, Gao B, Merrick D, Patil T, DeGregori J, Camidge DR, Pine, SR, SabaawyHE. Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and
rationally designed drug screens. 2024; 24-A-5910-AACR.